MTORC1 and mTORC2 in energy homeostasis

Enzymes

Volumn 28, Issue C, 2010, Pages 263-278

  Cornu, Marion ^a   Hall, Michael N ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957236816     PISSN: 18746047     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1874-6047(10)28013-7     Document Type: Book

References (103)

1. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
2. Kwiatkowski D.J., et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 2002, 11:525-534.
3. El-Hashemite N., Zhang H., Henske E.P., Kwiatkowski D.J. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 2003, 361:1348-1349.
4. Kobayashi T., Minowa O., Kuno J., Mitani H., Hino O., Noda T. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 1999, 59:1206-1211.
5. Onda H., Lueck A., Marks P.W., Warren H.B., Kwiatkowski D.J. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 1999, 104:687-695.
6. Gangloff Y.G., et al. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol Cell Biol 2004, 24:9508-9516.
7. Murakami M., et al. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol 2004, 24:6710-6718.
8. Guertin D.A., et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 2006, 11:859-871.
9. Jacinto E., et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006, 127:125-137.
10. Shiota C., Woo J.T., Lindner J., Shelton K.D., Magnuson M.A. Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell 2006, 11:583-589.
11. Yang Q., Inoki K., Ikenoue T., Guan K.L. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 2006, 20:2820-2832.
12. Sancak Y., et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008, 320:1496-1501.
13. Kim E., Goraksha-Hicks P., Li L., Neufeld T.P., Guan K.L. Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol 2008, 10:935-945.
14. Findlay G.M., Yan L., Procter J., Mieulet V., Lamb R.F. A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling. Biochem J 2007, 403:13-20.
15. Nobukuni T., et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci USA 2005, 102:14238-14243.
16. Byfield M.P., Murray J.T., Backer J.M. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem 2005, 280:33076-33082.
17. Gulati P., et al. Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34. Cell Metab 2008, 7:456-465.
18. Mizuno T.M., Kleopoulos S.P., Bergen H.T., Roberts J.L., Priest C.A., Mobbs C.V. Hypothalamic pro-opiomelanocortin mRNA is reduced by fasting and [corrected] in ob/ob and db/db mice, but is stimulated by leptin. Diabetes 1998, 47:294-297.
19. Shutter J.R., Graham M., Kinsey A.C., Scully S., Luthy R., Stark K.L. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev 1997, 11:593-602.
20. Cota D., et al. Hypothalamic mTOR signaling regulates food intake. Science 2006, 312:927-930.
21. Ropelle E.R., et al. A central role for neuronal AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) in high-protein diet-induced weight loss. Diabetes 2008, 57:594-605.
22. Mori H., et al. Critical role for hypothalamic mTOR activity in energy balance. Cell Metab 2009, 9:362-374.
23. Pocai A., et al. Restoration of hypothalamic lipid sensing normalizes energy and glucose homeostasis in overfed rats. J Clin Invest 2006, 116:1081-1091.
24. Hu Z., Dai Y., Prentki M., Chohnan S., Lane M.D. A role for hypothalamic malonyl-CoA in the control of food intake. J Biol Chem 2005, 280:39681-39683.
25. Clegg D.J., Wortman M.D., Benoit S.C., McOsker C.C., Seeley R.J. Comparison of central and peripheral administration of C75 on food intake, body weight, and conditioned taste aversion. Diabetes 2002, 51:3196-3201.
26. Wortman M.D., Clegg D.J., D'Alessio D., Woods S.C., Seeley R.J. C75 inhibits food intake by increasing CNS glucose metabolism. Nat Med 2003, 9:483-485.
27. Lam T.K., Schwartz G.J., Rossetti L. Hypothalamic sensing of fatty acids. Nat Neurosci 2005, 8:579-584.
28. Loftus T.M., et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 2000, 288:2379-2381.
29. Proulx K., Cota D., Woods S.C., Seeley R.J. Fatty acid synthase inhibitors modulate energy balance via mammalian target of rapamycin complex 1 signaling in the central nervous system. Diabetes 2008, 57:3231-3238.
30. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
31. Gwinn D.M., et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008, 30:214-226.
32. Minokoshi Y., et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004, 428:569-574.
33. Ruderman N.B., et al. AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. Acta Physiol Scand 2003, 178:435-442.
34. Gao S., et al. Leptin activates hypothalamic acetyl-CoA carboxylase to inhibit food intake. Proc Natl Acad Sci USA 2007, 104:17358-17363.
35. Cao R., Lee B., Cho H.Y., Saklayen S., Obrietan K. Photic regulation of the mTOR signaling pathway in the suprachiasmatic circadian clock. Mol Cell Neurosci 2008, 38:312-324.
36. Cao R, Li A, Cho HY, Lee B, Obrietan K. Mammalian target of rapamycin signaling modulates photic entrainment of the suprachiasmatic circadian clock. J Neurosci 30:6302-6314.
37. Pende M., et al. Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature 2000, 408:994-997.
38. Ruvinsky I., et al. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev 2005, 19:2199-2211.
39. Mori H., et al. Critical roles for the TSC-mTOR pathway in {beta}-cell function. Am J Physiol Endocrinol Metab 2009, 297:E1013-E1022.
40. Rachdi L., et al. Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1-dependent manner. Proc Natl Acad Sci USA 2008, 105:9250-9255.
41. Shigeyama Y., et al. Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice. Mol Cell Biol 2008, 28:2971-2979.
42. Hamada S., et al. Upregulation of the mammalian target of rapamycin complex 1 pathway by Ras homolog enriched in brain in pancreatic beta-cells leads to increased beta-cell mass and prevention of hyperglycemia. Diabetes 2009, 58:1321-1332.
43. Bussiere C.T., Lakey J.R., Shapiro A.M., Korbutt G.S. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 2006, 49:2341-2349.
44. da Silva Xavier G., Leclerc I., Varadi A., Tsuboi T., Moule S.K., Rutter G.A. Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. Biochem J 2003, 371:761-774.
45. Richards S.K., Parton L.E., Leclerc I., Rutter G.A., Smith R.M. Over-expression of AMP-activated protein kinase impairs pancreatic {beta}-cell function in vivo. J Endocrinol 2005, 187:225-235.
46. Leclerc I., et al. Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab 2004, 286:E1023-E1031.
47. Kefas B.A., et al. AICA-riboside induces apoptosis of pancreatic beta cells through stimulation of AMP-activated protein kinase. Diabetologia 2003, 46:250-254.
48. Riboulet-Chavey A., Diraison F., Siew L.K., Wong F.S., Rutter G.A. Inhibition of AMP-activated protein kinase protects pancreatic beta-cells from cytokine-mediated apoptosis and CD8+ T-cell-induced cytotoxicity. Diabetes 2008, 57:415-423.
49. Fu A., et al. Loss of Lkb1 in adult beta cells increases beta cell mass and enhances glucose tolerance in mice. Cell Metab 2009, 10:285-295.
50. Granot Z., et al. LKB1 regulates pancreatic beta cell size, polarity, and function. Cell Metab 2009, 10:296-308.
51. Sun G., et al. LKB1 deletion with the RIP.Cre-transgene modifies pancreatic {beta}-cell morphology and enhances insulin secretion in vivo. Am J Physiol Endocrinol Metab 2010, 298:E1261-E1273.
52. Fraenkel M., et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008, 57:945-957.
53. Hennige A.M., et al. Upregulation of insulin receptor substrate-2 in pancreatic beta cells prevents diabetes. J Clin Invest 2003, 112:1521-1532.
54. Withers D.J., Burks D.J., Towery H.H., Altamuro S.L., Flint C.L., White M.F. Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat Genet 1999, 23:32-40.
55. Lingohr M.K., Dickson L.M., McCuaig J.F., Hugl S.R., Twardzik D.R., Rhodes C.J. Activation of IRS-2-mediated signal transduction by IGF-1, but not TGF-alpha or EGF, augments pancreatic beta-cell proliferation. Diabetes 2002, 51:966-976.
56. Briaud I., Dickson L.M., Lingohr M.K., McCuaig J.F., Lawrence J.C., Rhodes C.J. Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells. J Biol Chem 2005, 280:2282-2293.
57. Gimeno R.E., Klaman L.D. Adipose tissue as an active endocrine organ: recent advances. Curr Opin Pharmacol 2005, 5:122-128.
58. Shi Y., Burn P. Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nat Rev Drug Discov 2004, 3:695-710.
59. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
60. Colombani J., Raisin S., Pantalacci S., Radimerski T., Montagne J., Leopold P. A nutrient sensor mechanism controls Drosophila growth. Cell 2003, 114:739-749.
61. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
62. Polak P., Hall M.N. mTOR and the control of whole body metabolism. Curr Opin Cell Biol 2009, 21:209-218.
63. Bell A., Grunder L., Sorisky A. Rapamycin inhibits human adipocyte differentiation in primary culture. Obes Res 2000, 8:249-254.
64. Cho H.J., Park J., Lee H.W., Lee Y.S., Kim J.B. Regulation of adipocyte differentiation and insulin action with rapamycin. Biochem Biophys Res Commun 2004, 321:942-948.
65. El-Chaar D., Gagnon A., Sorisky A. Inhibition of insulin signaling and adipogenesis by rapamycin: effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1. Int J Obes Relat Metab Disord 2004, 28:191-198.
66. Gagnon A., Lau S., Sorisky A. Rapamycin-sensitive phase of 3T3-L1 preadipocyte differentiation after clonal expansion. J Cell Physiol 2001, 189:14-22.
67. Kim J.E., Chen J. regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 2004, 53:2748-2756.
68. Yeh W.C., Bierer B.E., McKnight S.L. Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. Proc Natl Acad Sci USA 1995, 92:11086-11090.
69. Polak P., Cybulski N., Feige J.N., Auwerx J., Ruegg M.A., Hall M.N. Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab 2008, 8:399-410.
70. Zhang H.H., et al. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One 2009, 4:e6189.
71. Um S.H., et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004, 431:200-205.
72. Le Bacquer O., et al. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest 2007, 117:387-396.
73. Cybulski N., Polak P., Auwerx J., Ruegg M.A., Hall M.N. mTOR complex 2 in adipose tissue negatively controls whole-body growth. Proc Natl Acad Sci USA 2009, 106:9902-9907.
74. Kumar A., et al. Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole body glucose and lipid metabolism. Diabetes 2010, 59:1397-1406.
75. Kloting N., et al. Autocrine IGF-1 action in adipocytes controls systemic IGF-1 concentrations and growth. Diabetes 2008, 57:2074-2082.
76. Bodine S.C., et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001, 3:1014-1019.
77. Pallafacchina G., Calabria E., Serrano A.L., Kalhovde J.M., Schiaffino S. A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc Natl Acad Sci USA 2002, 99:9213-9218.
78. Izumiya Y., et al. Fast/Glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metab 2008, 7:159-172.
79. Ohanna M., et al. Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat Cell Biol 2005, 7:286-294.
80. Bentzinger C.F., et al. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab 2008, 8:411-424.
81. Handschin C., et al. Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1alpha muscle-specific knock-out animals. J Biol Chem 2007, 282:30014-30021.
82. Cunningham J.T., Rodgers J.T., Arlow D.H., Vazquez F., Mootha V.K., Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 2007, 450:736-740.
83. Schieke S.M., et al. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J Biol Chem 2006, 281:27643-27652.
84. Aguilar V., et al. S6 kinase deletion suppresses muscle growth adaptations to nutrient availability by activating AMP kinase. Cell Metab 2007, 5:476-487.
85. Kumar A., Harris T.E., Keller S.R., Choi K.M., Magnuson M.A., Lawrence J.C. Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances Basal glycogen synthase activity. Mol Cell Biol 2008, 28:61-70.
86. Postic C., Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008, 118:829-838.
87. Eberle D., Hegarty B., Bossard P., Ferre P., Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 2004, 86:839-848.
88. Shimano H., Horton J.D., Shimomura I., Hammer R.E., Brown M.S., Goldstein J.L. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 1997, 99:846-854.
89. Horton J.D., et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci USA 2003, 100:12027-12032.
90. Horton J.D., Shimomura I., Brown M.S., Hammer R.E., Goldstein J.L., Shimano H. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J Clin Invest 1998, 101:2331-2339.
91. Shimomura I., Shimano H., Horton J.D., Goldstein J.L., Brown M.S. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 1997, 99:838-845.
92. Becard D., Hainault I., Azzout-Marniche D., Bertry-Coussot L., Ferre P., Foufelle F. Adenovirus-mediated overexpression of sterol regulatory element binding protein-1c mimics insulin effects on hepatic gene expression and glucose homeostasis in diabetic mice. Diabetes 2001, 50:2425-2430.
93. Liang G., Yang J., Horton J.D., Hammer R.E., Goldstein J.L., Brown M.S. Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem 2002, 277:9520-9528.
94. Yahagi N., et al. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 2002, 277:19353-19357.
95. Brown N.F., Stefanovic-Racic M., Sipula I.J., Perdomo G. The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes. Metabolism 2007, 56:1500-1507.
96. Mauvoisin D., Rocque G., Arfa O., Radenne A., Boissier P., Mounier C. Role of the PI3-kinase/mTor pathway in the regulation of the stearoyl CoA desaturase (SCD1) gene expression by insulin in liver. J Cell Commun Signal 2007, 1:113-125.
97. Porstmann T., et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 2008, 8:224-236.
98. Li S, Brown MS, Goldstein JL, Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci USA107: 3441-3446.
99. Shaw R.J., et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005, 310:1642-1646.
100. Tzatsos A., Kandror K.V. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 2006, 26:63-76.
101. Zhou G., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108:1167-1174.
102. Zang M., et al. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 2004, 279:47898-47905.
103. Koketsu Y., et al. Hepatic overexpression of a dominant negative form of raptor enhances Akt phosphorylation and restores insulin sensitivity in K/KAy mice. Am J Physiol Endocrinol Metab 2008, 294:E719-E725.